Verona Pharma plc
VRNA
$105.28
$0.080.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 102.94M | 71.26M | 36.64M | 5.62M | -- |
| Total Other Revenue | 199.00K | 5.00M | 18.00K | -- | -- |
| Total Revenue | 103.14M | 76.26M | 36.66M | 5.62M | -- |
| Cost of Revenue | 4.76M | 3.41M | 2.04M | 543.00K | -- |
| Gross Profit | 98.38M | 72.85M | 34.62M | 5.08M | -- |
| SG&A Expenses | 72.13M | 69.11M | 45.09M | 35.20M | 49.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.83M | 86.57M | 54.44M | 44.68M | 67.58M |
| Operating Income | 13.31M | -10.32M | -17.78M | -39.06M | -67.58M |
| Income Before Tax | 11.88M | -16.56M | -25.56M | -42.71M | -69.82M |
| Income Tax Expenses | -39.00K | -239.00K | 8.27M | 250.00K | 1.01M |
| Earnings from Continuing Operations | 11.92M | -16.32M | -33.83M | -42.96M | -70.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.92M | -16.32M | -33.83M | -42.96M | -70.84M |
| EBIT | 13.31M | -10.32M | -17.78M | -39.06M | -67.58M |
| EBITDA | 13.60M | -10.02M | -17.52M | -38.79M | -67.31M |
| EPS Basic | 1.11 | -1.54 | -3.26 | -4.22 | -6.99 |
| Normalized Basic EPS | 0.09 | -0.12 | -0.19 | -0.33 | -0.51 |
| EPS Diluted | 1.11 | -1.54 | -3.52 | -4.22 | -7.04 |
| Normalized Diluted EPS | 0.08 | -0.12 | -0.19 | -0.33 | -0.51 |
| Average Basic Shares Outstanding | 85.64M | 84.93M | 82.91M | 81.49M | 81.03M |
| Average Diluted Shares Outstanding | 11.36M | 10.62M | 10.36M | 10.19M | 10.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |